GSK Exits Consumer Health With Haleon Launch
Executive Summary
The global market leader in consumer health is now Haleon following its separation from GSK after more than two years of planning.
You may also be interested in...
Nicorette Gum Package Front In US Adds Initial, Zyrtec Labeling Gets ‘New’ For Limited Time
Front panels for 34 SKUs for Haleon’s Nicorette 2- and 4-mg gum in approved to include a superimposed letter N; labeling approved for seven SKUs for Kenvue’s Zyrtec Allergy 5- and 10-mg tablets to include “new” for six months.
J&J Has Kenvue IPO Roadshow In One Lane, Potentially Long Road For Talc Litigation In Other
Roadshow stated for IPO planned for before end of 2023 of 151.2m shares of Kenvue common stock currently expected at between $20 and $23 per share. Analysts positive on IPO but caution launch wouldn’t come problem-free.
Relief For Excedrin Migraine, Green For Package
Approved changes are for primary display panel on immediate container and outer carton for total of eight packages, from 24- to 300-count, and include making the brand name Excedrin Migraine Relief.